Klippel-Feil syndrome in a boy exposed inadvertently to cyclophosphamide during pregnancy: A case report

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 94, Issue 4, 2012, Pages 249-252

  Lazalde, Brissia ^a,b   Grijalva Flores, Jesús ^a   Guerrero Romero, Fernando ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b UNIVERSIDAD JUÁREZ DEL ESTADO DE DURANGO   (Mexico)

Author keywords

Cyclophosphamide; Embryopathy; Klippel Feil syndrome; Teratogenesis; Vertebral anomalies

Indexed keywords

CYCLOPHOSPHAMIDE; PREDNISONE;

ADULT; ARTICLE; CASE REPORT; CHILD; COMPUTER ASSISTED TOMOGRAPHY; FACE DYSMORPHIA; FEMALE; FIRST TRIMESTER PREGNANCY; HEARING LOSS; HUMAN; HYPOSPADIAS; INTRAUTERINE GROWTH RETARDATION; KLIPPEL FEIL SYNDROME; MALE; ORCHIDOPEXY; PREGNANCY; PRIORITY JOURNAL; SCHOOL CHILD; ULTRASOUND;

CHILD; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KLIPPEL-FEIL SYNDROME; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; TERATOGENS;

ANIMALIA; MAMMALIA;

EID: 84859621761     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.23004     Document Type: Article

References (35)

1. Bauman GI. 1932. Absence of the cervical spine: Klippel-Feil syndrome. JAMA 98: 129-132.
2. Bizarro AH. 1938. Brevicollis. Lancet 232: 828-829.
3. Busquet F, Nagel R, von Landenberg F, et al. 2008. Development of a new screening assay to identify proteratogenic substances using zebrafish danio rerio embryo combined with an exogenous mammalian metabolic activation system (mDarT). Toxicol Sci 104: 177-188.
4. Chen CS, Lin JT, Goss KA, et al. 2004. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol 65: 1278-1285.
5. Clemmesen V. 1936. Congenital cervical synostosis (Klippel-Feil's syndrome): four cases. Acta Radiol 17: 480-490.
6. Da Silva EO. 1982. Autosomal recessive Klippel-Feil syndrome. J Med Genet 19: 130-134.
7. Enns GM, Roeder E, Chan RT, et al. 1999. Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype? Am J Med Genet 86: 237-241.
8. Erskine CA. 1946. An analysis of the Klippel-Feil syndrome. Arch Pathol (Chic) 41: 269-281.
9. Giannakopoulou C, Manoura A, Hatzidaki E, et al. 2000. Multimodal cancer chemotherapy during the first and second trimester of pregnancy: a case report. Eur J Obstet Gynecol Reprod Biol 91: 95-97.
10. Gilani SH, Chatzinoff M. 1983. Embryopathic effects of cyclophosphamide. Environ Res 31: 296-301.
11. Greenberg LH, Tanaka KR. 1964. Congenital anomalies probably induced by cyclophosphamide. JAMA 188: 423-426.
12. Hensinger RN, Lang JE, MacEwen GD. 1974. Klippel-Feil syndrome; a constellation of associated anomalies. J Bone Joint Surg Am 56: 1246-1253.
13. Juberg RC, Gershanik JJ. 1976. Cervical vertebral fusion (Klippel-Feil) syndrome with consanguineous parents. J Med Genet 13: 246-249.
14. Kirshon B, Wasserstrum N, Willis R, et al. 1988. Teratogenic effects of first-trimester cyclophosphamide therapy. Obstet Gynecol 72(3 Pt 2): 462-464.
15. Lowry RB. 1977. The Klippel-Feil anomalad as part of the fetal alcohol syndrome. Teratology 16: 53-56.
16. Mirkes PE. 1985. Cyclophosphamide teratogenesis: a review. Teratog Carcinog Mutagen 5: 75-88.
17. Moore WB, Matthews TJ, Rabinowitz R. 1975. Genitourinary anomalies associated with Klippel-Feil syndrome. J Bone Joint Surg Am 57: 355-357.
18. Murray CL, Reichert JA, Anderson J, Twiggs LB. 1984. Multimodal cancer therapy for breast cancer in the first trimester of pregnancy. A case report. JAMA 252: 2607-2608.
19. Mutchinick O, Aizpuru E, Grether P, et al. 1992. The human teratogenic effect of cyclophosphamide. Aust Terat Abs 45: 329.
20. Nakajima M, Komagata S, Fujiki Y, et al. 2007. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics 17: 431-445.
21. Narang M, Goyal JP. 2006. Uncommon manifestations of Klippel Feil syndrome. Indian Pediatr 43: 265-266.
22. Ozolins TR. 2010. Cyclophosphamide and the Teratology Society: an awkward marriage. Birth Defects Res B Dev Reprod Toxicol 89: 289-299.
23. Paladini D, Vassallo M, D'Armiento MR, et al. 2004. Prenatal detection of multiple fetal anomalies following inadvertent exposure to cyclophosphamide in the first trimester of pregnancy. Birth Defects Res A Clin Mol Teratol 70: 99-100.
24. Paskulin GA, Gazzola Zen PR, de Camargo Pinto LL, et al. 2005. Combined chemotherapy and teratogenicity. Birth Defects Res A Clin Mol Teratol 73: 634-637.
25. Rooseboom M, Commandeur JN, Vermeulen NP. 2004. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 56: 53-102.
26. Sadler TW. 2003. Skeletal system. In: Sadler TW, editor. Langman's Medical Embryology. Baltimore: Williams & Wilkins. pp. 193-194.
27. Schilgen M, Loeser H. 1994. Klippel-Feil anomaly combined with fetal alcohol syndrome. Eur Spine J 3: 289-290.
28. Schwartz PS, Waxman DJ. 2001. Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells. Mol Pharmacol 60: 1268-1279.
29. Singh S. 1971. The teratogenicity of cyclophosphamide (endoxan-asta) in rats. Indian J Med Res 59: 1128-1135.
30. Toledo TM, Harper RC, Moser RH. 1971. Fetal effects during cyclophosphamide and irradiation therapy. Ann Intern Med 74: 87-91.
31. Tracy MR, Dormans JP, Kusumi K. 2004. Klippel-Feil syndrome: clinical features and current understanding of etiology. Clin Orthop Relat Res 424: 183-190.
32. Vaux KK, Kahole NC, Jones KL. 2003. Cyclophosphamide, methotrexate, and cytarabine embryopathy: is apoptosis the common pathway? Birth Defects Res A Clin Mol Teratol 67: 403-408.
33. Xie HJ, Yasar U, Lundgren S, et al. 2003. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 3: 53-61.
34. Zankl A, Eberle L, Molinari L, Schinzel A. 2002. Growth charts for nose length, nasal protrusion, and philtrum length from birth to 97 years. Am J Med Genet 111: 388-391.
35. Zemlickis D, Lishner M, Erlich R, Koren G. 1993. Teratogenicity and carcinogenicity in a twin exposed in utero to cyclophosphamide. Teratog Carcinog Mutagen 13: 139-143.